logo-loader
viewGENFIT

Genfit SA expecting Phase 3 results of its NASH therapy by 1Q

Genfit SA (NASDAQ:GNFT) CEO Pascal Prigent sat down with Proactive’s Christine Corrado at BIO CEO in New York.

The biopharmaceutical company, based in France, is developing therapeutic and diagnostic solutions for metabolic and liver related diseases.

Quick facts: GENFIT

Price: 17.86 USD

NASDAQ:GNFT
Market: NASDAQ
Market Cap: $693.53 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Chaarat Gold's Dusty Nicol talks increase to reserves at Tulkubash

Chaarat Gold Holdings Ltd's (LON:CGH) Dusty Nicol caught up with Proactive London's Andrew Scott to talk through the increase in reserves that's been announced for its Tulkubash project in Kyrgyz Republic. It follows last year's 20,000 metre drilling programme. Proven & probable...

7 hours, 8 minutes ago

2 min read